Guardant Health (GH) saw its shares surge in the last session with trading volume being higher than average. The latest trend ...

On Sunday, Arcellx, Inc. (NASDAQ:ACLX) revealed new data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma ...

Oppenheimer laid out five “aspirational” potential takeover targets in biotech heading into the annual JPMorgan Health Care Conference. “We ...

The firm lists Blueprint Medicines (BPMC), Janux Therapeutics (JANX), Arcellx (ACLX), Nuvalent (NUVL), and Viking Therapeutics (VKTX) as possible takeout targets in biotechnology. Discover the ...

Buy ACLX near 69.41 target 83.68 stop loss @ 69.21 Details The technical summary data tells us to buy ACLX near 69.41 with an upside target of 83.68. This data also tells us to set a stop loss @ 69.21 ...

Ahead of the 2025 J.P. Morgan Healthcare Conference scheduled to take place in a few days, Oppenheimer named five potential buyout candidates in biotech on Friday, naming obesity drug developer Viking ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies are ...

The division, which will expand on the already-existing Released Soldiers’ Division and Fund, will include a dedicated branch for reservists’ welfare and be led by Col. (res.) Eyal Hans ...

Ahead of the 2025 J.P. Morgan Healthcare Conference scheduled to take place in a few days, Oppenheimer named five potential buyout candidates in biotech on Friday, naming obesity drug developer ...